12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Obeticholic acid: Phase II data

A double-blind, international Phase II trial in 59 patients with elevated alkaline phosphatase showed that once-daily 10 and 50 mg INT-747 met the primary endpoint of significantly reducing alkaline phosphatase levels from baseline to week 12 vs. placebo (45% and 38%, respectively, vs. 0%; p<0.0001 for both)....

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >